FDA ApprovedUnited States
Ameluz Red-Light PDT Now FDA-Approved for Superficial Basal Cell Skin Cancer
Ameluz (aminolevulinic acid HCl 10% gel) — red-light PDT for superficial basal cell carcinoma
FDA labelled expansion on 9 September 2026 (sNDA 208081/S-040; Prescribing Information Revised 09/2026) for Ameluz (aminolevulinic acid hydrochloride) topical…
This is for adults with superficial basal cell carcinoma — and the caregivers helping them — who may be candidates for labelled US Ameluz red-light PDT with a…